NeuroMetrix (NURO)
(Delayed Data from NSDQ)
$3.93 USD
+0.11 (2.88%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.83 -0.10 (-2.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.93 USD
+0.11 (2.88%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.83 -0.10 (-2.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Insulet (PODD) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Analysts Estimate NeuroMetrix (NURO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate NeuroMetrix (NURO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: NeuroMetrix (NURO) Q1 Earnings Expected to Decline
by Zacks Equity Research
NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Medical Product Stocks Likely to Top Q3 Earnings Estimates
by Zacks Equity Research
The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.